# Dietary fiber inulin mitigates peripheral neuropathy in different stages of diabetes via modulating gut microbiota and metabolites in db/db mice

**Authors:** Ke Li, Wenjun Fu, Yuanyuan Liu, Jing Xue, Xiaoli Yang, Leiwen Wang, Jin Xu, Junbai Ma, Rong Su, Xia Yang, Yuning Sun, Hao Wang

PMC · DOI: 10.1371/journal.pone.0336962 · PLOS One · 2025-11-20

## TL;DR

Inulin, a type of dietary fiber, helps reduce nerve damage in diabetic mice by improving gut health and reducing inflammation.

## Contribution

This study shows inulin's neuroprotective effects against diabetic peripheral neuropathy in different diabetes stages via gut microbiota and metabolite modulation.

## Key findings

- Inulin reduced neuropathic symptoms like pain sensitivity and nerve conduction issues in prediabetic and diabetic mice.
- Inulin lowered pro-inflammatory cytokines and increased anti-inflammatory IL-10 in prediabetic mice.
- Inulin altered gut microbiota, increasing beneficial bacteria and decreasing harmful ones, which correlated with metabolic and inflammatory improvements.

## Abstract

The pathogenesis underlying diabetic peripheral neuropathy (DPN) remains largely elusive. Due to current unsatisfactory therapeutic approaches, new strategies for the control of DPN are needed. The present study was designed to assess whether inulin could serve as a potential neuroprotection against DPN in diverse stages of diabetes. Leptin receptor-mutant db/db mice were used as a model for DPN to dynamically assess the effects of inulin on DPN in diverse diabetic groups. According to blood glucose, the mice were randomly divided into prediabetes group (PDM group), inulin treated prediabetes group (INU/PDM group), diabetes group (DM group) and inulin treated diabetes group (INU/DM group). After 6 weeks of treatment, we found that inulin supplementation attenuated the neuropathic phenotypes in PDM and DM, including mechanical allodynia, thermal hyperalgesia and nerve conduction. Furthermore, inulin administration remarkably suppressed the levels of pro-inflammatory IL-6, TNF-α, and IL-17A in diverse diabetic groups with DPN, but increased an anti-inflammatory IL-10 in INU/PDM group, suggesting that dietary inulin intervention may suppress the DPN inflammation in different diabetic stages. Moreover, inulin supplementation markedly reduced the circulating LPS translocation. Metabolomics analysis revealed that inulin treatment significantly modulated the levels of 8 stage-specific metabolites; notably, it increased anti-inflammatory, anti-diabetic and neuroprotective metabolites taurine and dodecanoic acid in prediabetic mice, while decreasing pro-inflammatory mediators including oleamide and adrenic acid. In diabetic mice, inulin elevated metabolites including methylation (S-Adenosylmethionine), glucose homeostasis (glucose 6-phosphate), N-acetyl-L-phenylalanine and quinate. These metabolites are implicated in pathways such as bile acid metabolism, fatty acid oxidation, and neurotransmitter regulation, suggesting that inulin may exert neuroprotective effects by restoring metabolic homeostasis in a stage-dependent manner. Furthermore, rectification of gut dysbiosis by dietary inulin administration, with a major impact on increasing intestinal beneficial bacteria |(Bacteroides and Cyanobacteria) and decreasing pro-inflammatory bacteria (Ruminiclostridium_6, Mucispirillum, Deferribacteres and Tenericutes), exerted a close and complex interactions with metabolites, inflammatory factors, and peripheral neuropathic indicators. Collectively, dietary inulin intervention ameliorated DPN via reshaping gut microbial metabolism and suppressing inflammation, which may potentially provide an effective and safe therapeutics for the control of the disease.

## Linked entities

- **Proteins:** IL6 (interleukin 6), TNF (tumor necrosis factor), IL17A (interleukin 17A), IL10 (interleukin 10), IRF6 (interferon regulatory factor 6)
- **Chemicals:** taurine (PubChem CID 1123), dodecanoic acid (PubChem CID 3893), oleamide (PubChem CID 5283387), adrenic acid (PubChem CID 5497181), quinate (PubChem CID 6508)
- **Diseases:** diabetes (MONDO:0005015)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Lepr (leptin receptor) [NCBI Gene 16847] {aka B219, LEP-R, LEPROT, Leprb, Modb1, OB-RGRP}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}
- **Diseases:** DM (MESH:D009223), mechanical allodynia (MESH:D006930), gut dysbiosis (MESH:D064806), prediabetes (MESH:D011236), neuropathic (MESH:D009437), inflammation (MESH:D007249), diabetes (MESH:D003920), DPN (MESH:D010523)
- **Chemicals:** dodecanoic acid (MESH:C030358), S-Adenosylmethionine (MESH:D012436), adrenic acid (MESH:C011395), inulin (MESH:D007444), LPS (MESH:D008070), INU (-), bile acid (MESH:D001647), oleamide (MESH:C029407), blood glucose (MESH:D001786), quinate (MESH:D011801), taurine (MESH:D013654), N-acetyl-L-phenylalanine (MESH:C044228), glucose (MESH:D005947), glucose 6-phosphate (MESH:D019298), fatty acid (MESH:D005227)
- **Species:** Cyanobacteriota (blue-green algae, phylum) [taxon 1117], Bacteroides (genus) [taxon 816], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12633925/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12633925/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12633925/full.md

---
Source: https://tomesphere.com/paper/PMC12633925